Highlights & Basics
- Peptic ulcers usually present as chronic, upper abdominal pain related to eating a meal (dyspepsia).
- Use of nonsteroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori infection are the most common causes.
- There may be some epigastric tenderness, but often there are no other signs on physical exam.
- Endoscopy is diagnostic and may show an ulcer in the stomach or proximal duodenum. H pylori infection should be sought.
- In the absence of "alarm" (red flag) symptoms or signs, testing for and treating H pylori and/or empiric acid inhibition therapy is appropriate.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Citations
Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024 Sep 1;119(9):1730-53.[Abstract][Full Text]
Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017 Jul;112(7):988-1013.[Abstract][Full Text]
Laine L, Barkun AN, Saltzman JR, et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021 May 1;116(5):899-917.[Abstract]
1. Sung JJ, Kuipers EJ, El-Serag HB. Systematic review: the global incidence and prevalence of peptic ulcer disease. Aliment Pharmacol Ther. 2009 May 1;29(9):938-46.[Abstract][Full Text]
2. Li Z, Zou D, Ma X, et al. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China. Am J Gastroenterol. 2010 Aug 24;105(12):2570-7.[Abstract]
3. Aro P, Storskrubb T, Ronkainen J, et al. Peptic ulcer disease in a general adult population: the Kalixanda study: a random population-based study. Am J Epidemiol. 2006 Jun 1;163(11):1025-34.[Abstract]
4. Vakil N. Peptic ulcer disease: a review. JAMA. 2024 Dec 3;332(21):1832-42.[Abstract]
5. Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther. 1995;9 Suppl 2:3-12.[Abstract]
6. Cai S, García Rodríguez LA, Massó-González EL, et al. Uncomplicated peptic ulcer in the UK: trends from 1997 to 2005. Aliment Pharmacol Ther. 2009 Nov 15;30(10):1039-48.[Abstract][Full Text]
7. Nam K, Shin JE, Kim SE, et al. Prevalence and risk factors for upper gastrointestinal diseases in health check-up subjects: a nationwide multicenter study in Korea. Scand J Gastroenterol. 2018 Aug;53(8):910-6.[Abstract]
8. Sonnenberg A, Turner KO, Genta RM. Low prevalence of Helicobacter pylori-positive peptic ulcers in private outpatient endoscopy centers in the United States. Am J Gastroenterol. 2020 Feb;115(2):244-50.[Abstract]
9. Ran J, Jin X, Li J, et al. The global burden of peptic ulcer disease in 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Int J Epidemiol. 2022 Oct 13;51(5):1666-76.[Abstract][Full Text]
10. Azhari H, King JA, Coward S, et al. The global incidence of peptic ulcer disease is decreasing since the turn of the 21st century: a study of the organisation for economic co-operation and development (OECD). Am J Gastroenterol. 2022 Sep 1;117(9):1419-27.[Abstract]
11. Suerbaum S, Michetti P. Helicobacter pylori infection. New Engl J Med. 2002 Oct 10;347(15):1175-86.[Abstract]
12. Archampong TN, Asmah RH, Richards CJ, et al. Gastro-duodenal disease in Africa: literature review and clinical data from Accra, Ghana. World J Gastroenterol. 2019 Jul 14;25(26):3344-58.[Abstract][Full Text]
13. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002 Jan 5;359(9300):14-22.[Abstract]
14. Miyake K, Kusunoki M, Shinji Y, et al. Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol. 2009;44(2):113-20.[Abstract]
15. Stollman N, Metz DC. Pathophysiology and prophylaxis of stress ulcer in intensive care unit patients. J Crit Care. 2005 Mar;20(1):35-45.[Abstract]
16. Chatzipanagiotou O, Schizas D, Vailas M, et al. All you need to know about gastrinoma today | gastrinoma and Zollinger-Ellison syndrome: a thorough update. J Neuroendocrinol. 2023 Apr;35(4):e13267.[Abstract]
17. Tsamakidis K, Panotopoulou E, Dimitroulopoulos D, et al. Herpes simplex virus type 1 in peptic ulcer disease: an inverse association with Helicobacter pylori. World J Gastroenterol. 2005 Nov 14;11(42):6644-9.[Abstract][Full Text]
18. The American Journal of Gastroenterology. Inpatient outcomes of peptic ulcer disease in HIV-positive patients in the United States. Oct 2025 [internet publication].[Full Text]
19. Callaghan J, Brown S, Battcock T, et al. Aggressive Helicobacter pylori-negative peptic ulceration as the initial manifestation of Crohn's disease. Frontline Gastroenterol. 2012 Jul;3(3):201-205.[Abstract][Full Text]
20. Hung LC, Ching JY, Sung JJ, et al. Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology. 2005 Jun;128(7):1845-50.[Abstract]
21. Dore MP, Soro S, Niolu C, et al. Clinical features and natural history of idiopathic peptic ulcers: a retrospective case-control study. Scand J Gastroenterol. 2019 Nov;54(11):1315-21.[Abstract]
22. Levenstein S, Rosenstock S, Jacobsen RK, et al. Psychological stress increases risk for peptic ulcer, regardless of Helicobacter pylori infection or use of nonsteroidal anti-inflammatory drugs. Clin Gastroenterol Hepatol. 2015 Mar;13(3):498-506.e1.[Abstract][Full Text]
23. Kanno T, Iijima K, Abe Y, et al. Peptic ulcers after the Great East Japan earthquake and tsunami: possible existence of psychosocial stress ulcers in humans. J Gastroenterol. 2013 Apr;48(4):483-90.[Abstract]
24. Cekin AH, Taskoparan M, Duman A, et al. The role of Helicobacter pylori and NSAIDs in the pathogenesis of uncomplicated duodenal ulcer. Gastroenterol Res Pract. 2012;2012:189373.[Abstract][Full Text]
25. Narayanan M, Reddy KM, Marsicano E. Peptic ulcer disease and Helicobacter pylori infection. Mo Med. 2018 May-Jun;115(3):219-24.[Abstract][Full Text]
26. O'Connor HJ. The role of Helicobacter pylori in peptic ulcer disease. Scand J Gastroenterol Suppl. 1994;201:11-5.[Abstract]
27. Lazzaroni M, Bianchi Porro G. Gastrointestinal side-effects of traditional nonsteroidal anti-inflammatory drugs and new formulations. Aliment Pharmacol Ther. 2004 Jul;20(suppl 2):48-58.[Abstract]
28. Russell RI. Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions. Postgrad Med J. 2001 Feb;77(904):82-8.[Abstract][Full Text]
29. Drini M. Peptic ulcer disease and non-steroidal anti-inflammatory drugs. Aust Prescr. 2017 Jun;40(3):91-3.[Abstract][Full Text]
30. Mahady SE, Margolis KL, Chan A, et al. Major GI bleeding in older persons using aspirin: incidence and risk factors in the ASPREE randomised controlled trial. Gut. 2021 Apr;70(4):717-24.[Abstract][Full Text]
31. García Rodríguez LA, Lin KJ, Hernández-Díaz S, et al. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011 Mar 15;123(10):1108-15.[Abstract][Full Text]
32. Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by nonsteroidal anti-inflammatory drugs: systematic review. BMJ. 2004 Oct 23;329(7472):948.[Abstract]
33. Tang CL, Ye F, Liu W, Pan XL, et al. Eradication of Helicobacter pylori infection reduces the incidence of peptic ulcer disease in patients using nonsteroidal anti-inflammatory drugs: a meta-analysis. Helicobacter. 2012 Aug;17(4):286-96.[Abstract]
34. Garrow D, Delegge MH. Risk factors for gastrointestinal ulcer disease in the US population. Dig Dis Sci. 2009 Jan 22;55(1):66-72.[Abstract]
35. Maity P, Biswas K, Roy S, et al. Smoking and the pathogenesis of gastroduodenal ulcer--recent mechanistic update. Mol Cell Biochem. 2003 Nov;253(1-2):329-38.[Abstract]
36. Brenner H, Rothenbacher D, Bode G, et al. The individual and joint contributions of Helicobacter pylori infection and family history to the risk for peptic ulcer disease. J Infect Dis. 1998 Apr;177(4):1124-7.[Abstract]
37. Johnsen R, Førde OH, Straume B, et al. Aetiology of peptic ulcer: a prospective population study in Norway. J Epidemiol Community Health. 1994 Apr;48(2):156-60.[Abstract]
38. Del Bianco T, Borgoni R, Del Bianco P, et al. Peptic ulcer inheritance in patients with elevated serum pepsinogen group A levels and without infection of Helicobacter pylori. Dig Liver Dis. 2000 Jan-Feb;32(1):12-9.[Abstract]
39. Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009 Mar;104(3):728-38.[Abstract]
40. MacLaren R, Dionne JC, Granholm A, et al. Society of Critical Care Medicine and American Society of Health-System Pharmacists Guideline for the prevention of stress-related gastrointestinal bleeding in critically ill adults. Crit Care Med. 2024 Aug 1;52(8):e421-30.[Abstract][Full Text]
41. Scheiman JM, Devereaux PJ, Herlitz J, et al. Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). Heart. 2011 May;97(10):797-802.[Abstract][Full Text]
42. Kurlander JE, Barnes GD, Fisher A, et al. Association of antisecretory drugs with upper gastrointestinal bleeding in patients using oral anticoagulants: a systematic review and meta-analysis. Am J Med. 2022 Oct;135(10):1231-43.e8.[Abstract][Full Text]
43. Ahn HJ, Lee SR, Choi EK, et al. Protective effect of proton-pump inhibitor against gastrointestinal bleeding in patients receiving oral anticoagulants: a systematic review and meta-analysis. Br J Clin Pharmacol. 2022 Nov;88(11):4676-87.[Abstract]
44. Yang M, He M, Zhao M, et al. Proton pump inhibitors for preventing non-steroidal anti-inflammatory drug induced gastrointestinal toxicity: a systematic review. Curr Med Res Opin. 2017 Jan 25;33(6):973-80.[Abstract]
45. Hawkey C, Avery A, Coupland CAC, et al. Helicobacter pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (HEAT): a randomised, double-blind, placebo-controlled trial. Lancet. 2022 Nov 5;400(10363):1597-606.[Abstract][Full Text]
46. Chey WD, Howden CW, Moss SF, et al. ACG clinical guideline: treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024 Sep 1;119(9):1730-53.[Abstract][Full Text]
47. Cash BD. Evidence-based medicine as it applies to acid suppression in the hospitalized patient. Crit Care Med. 2002 Jun;30(suppl 6):S373-8.[Abstract]
48. Mutlu GM, Mutlu EA, Factor P. Prevention and treatment of gastrointestinal complications in patients on mechanical ventilation. Am J Respir Med. 2003;2(5):395-411.[Abstract]
49. Reynolds PM, MacLaren R. Re-evaluating the utility of stress ulcer prophylaxis in the critically ill patient: a clinical scenario-based meta-analysis. Pharmacotherapy. 2019 Mar;39(3):408-20.[Abstract]
50. Jones CA, Betthauser KD, Lizza BD, et al. Impact of stress ulcer prophylaxis discontinuation guidance in mechanically ventilated, critically ill patients: a pre-post cohort study. Hosp Pharm. 2022 Aug;57(4):510-7.[Abstract][Full Text]
51. Chan FK, Kyaw M, Tanigawa T, et al. Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology. 2016 Sep 15;152(1):105-10.e1.[Abstract]
52. Scally B, Emberson JR, Spata E, et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018 Apr;3(4):231-41.[Abstract][Full Text]
53. Garegnani L, Oltra G, Burgos MA, et al. Proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug-induced ulcers and dyspepsia. Cochrane Database Syst Rev. 2025 May 8;5(5):CD014585.[Abstract]
54. Gralnek IM, Stanley AJ, Morris AJ, et al. Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) guideline - update 2021. Endoscopy. 2021 Mar;53(3):300-32.[Abstract][Full Text]
55. Almadi MA, Lu Y, Alali AA, et al. Peptic ulcer disease. Lancet. 2024 Jul 6;404(10447):68-81.[Abstract]
56. Moayyedi PM, Lacy BE, Andrews CN, et al. ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol. 2017 Jul;112(7):988-1013.[Abstract][Full Text]
57. ASGE Standards of Practice Committee, Banerjee S, Cash BD, Dominitz JA, et al. The role of endoscopy in the management of patients with peptic ulcer disease. Gastrointest Endosc. 2010 Apr;71(4):663-8.[Abstract][Full Text]
58. National Institute for Health and Care Excellence. Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. Oct 2019 [internet publication].[Full Text]
59. American Society for Clinical Pathology. Thirty five things physicians should question. Choosing Wisely, an initiative of the ABIM Foundation. 2016 [internet publication].[Full Text]
60. Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022 Aug 8;gutjnl-2022-327745.[Abstract][Full Text]
61. Best LM, Takwoingi Y, Siddique S, et al. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;(3):CD012080.[Abstract][Full Text]
62. McNulty C, Teare L, Owen R, et al. Test and treat for dyspepsia--but which test? BMJ. 2005 Jan 15;330(7483):105-6.[Abstract]
63. American College of Radiology. ACR appropriateness criteria: nonvariceal upper gastrointestinal bleeding. 2024 [internet publication].[Full Text]
64. Sengupta N, Kastenberg DM, Bruining DH, et al. The role of imaging for GI bleeding: ACG and SAR consensus recommendations. Radiology. 2024 Mar;310(3):e232298.[Abstract][Full Text]
65. American College of Radiology. ACR appropriateness criteria®: epigastric pain. 2021 [internet publication].[Full Text]
66. Kamada T, Satoh K, Itoh T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol. 2021 Apr;56(4):303-22.[Abstract][Full Text]
67. Sung JJ, Chiu PW, Chan FKL, et al. Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Gut. 2018 Oct;67(10):1757-68.[Abstract][Full Text]
68. Laine L, Barkun AN, Saltzman JR, et al. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. Am J Gastroenterol. 2021 May 1;116(5):899-917.[Abstract]
69. Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. Ann Intern Med. 2019 Dec 3;171(11):805-22.[Abstract][Full Text]
70. Stanley AJ, Ashley D, Dalton HR, et al. Outpatient management of patients with low-risk upper-gastrointestinal haemorrhage: multicentre validation and prospective evaluation. Lancet. 2009 Jan 3;373(9657):42-7.[Abstract]
71. Srirajaskanthan R, Conn R, Bulwer C, et al. The Glasgow Blatchford scoring system enables accurate risk stratification of patients with upper gastrointestinal haemorrhage. Int J Clin Pract. 2010 Jun;64(7):868-74.[Abstract]
72. Alali AA, Barkun AN. An update on the management of non-variceal upper gastrointestinal bleeding. Gastroenterol Rep (Oxf). 2023;11:goad011.[Abstract][Full Text]
73. Coz Yataco AO, Soghier I, Hébert PC, et al. Red blood cell transfusion in critically ill adults: an American College of Chest Physicians clinical practice guideline. Chest. 2025 Feb;167(2):477-89.[Abstract][Full Text]
74. Abraham NS, Barkun AN, Sauer BG, et al. American College of Gastroenterology-Canadian Association of Gastroenterology clinical practice guideline: management of anticoagulants and antiplatelets during acute gastrointestinal bleeding and the periendoscopic period. Am J Gastroenterol. 2022 Apr 1;117(4):542-58.[Abstract][Full Text]
75. Cheung J, Rajala J, Moroz D, et al. Acetylsalicylic acid use in patients with acute myocardial infarction and peptic ulcer bleeding. Can J Gastroenterol. 2009 Sep;23(9):619-23.[Abstract][Full Text]
76. Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2010;152:1-9.[Abstract]
77. Hussein M, Alzoubaidi D, Lopez MF, et al. Hemostatic spray powder TC-325 in the primary endoscopic treatment of peptic ulcer-related bleeding: multicenter international registry. Endoscopy. 2021 Jan;53(1):36-43.[Abstract]
78. Hung WK, Li VK, Chung CK, et al. Randomized trial comparing pantoprazole infusion, bolus and no treatment on gastric pH and recurrent bleeding in peptic ulcers. ANZ J Surg. 2007 Aug;77(8):677-81.[Abstract]
79. Sung JJ, Barkun A, Kuipers EJ, et al. Intravenous esomeprazole for prevention of recurrent peptic ulcer bleeding: a randomized trial. Ann Intern Med. 2009 Apr 7;150(7):455-64.[Abstract][Full Text]
80. Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000 Aug 3;343(5):310-6.[Abstract][Full Text]
81. Kanno T, Yuan Y, Tse F, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2022 Jan 7;1(1):CD005415.[Abstract][Full Text]
82. Tarasconi A, Coccolini F, Biffl WL, et al. Perforated and bleeding peptic ulcer: WSES guidelines. World J Emerg Surg. 2020;15:3.[Abstract][Full Text]
83. Guo CG, Cheung KS, Zhang F, et al. Delay in retreatment of Helicobacter pylori infection increases risk of upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2021 Feb;19(2):314-22.e2.[Abstract][Full Text]
84. Dahal K, Sharma SP, Kaur J, et al. Efficacy and safety of proton pump inhibitors in the long-term aspirin users: a meta-analysis of randomized controlled trials. Am J Ther. 2017 Sep/Oct;24(5):e559-e569.[Abstract]
85. Nissen SE, Yeomans ND, Solomon DH, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016 Nov 13;375(26):2519-29.[Abstract][Full Text]
86. Richardson C, Hawkey CJ, Stack WA. Proton pump inhibitors - pharmacology and rationale for use in gastrointestinal disorders. Drugs. 1998 Sep;56(3):307-35.[Abstract]
87. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;(4):CD002296.[Abstract][Full Text]
88. Ford AC, Gurusamy KS, Delaney B, et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev. 2016;(4):CD003840.[Abstract][Full Text]
89. Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019 Jul;157(1):44-53.[Abstract][Full Text]
90. Flores-Treviño S, Mendoza-Olazarán S, Bocanegra-Ibarias P, et al. Helicobacter pylori drug resistance: therapy changes and challenges. Expert Rev Gastroenterol Hepatol. 2018 Aug;12(8):819-27.[Abstract]
91. Cummings LC, Hojat LS, Nguyen DC, et al. Tailored treatment based on Helicobacter pylori genetic markers of resistance is associated with higher eradication success. Am J Gastroenterol. 2023 Feb 1;118(2):360-3.[Abstract][Full Text]
92. Park CS, Lee SM, Park CH, et al. Pretreatment antimicrobial susceptibility-guided vs. clarithromycin-based triple therapy for Helicobacter pylori eradication in a region with high rates of multiple drug resistance. Am J Gastroenterol. 2014 Oct;109(10):1595-602.[Abstract]
93. Targownik LE, Fisher DA, Saini SD. AGA Clinical practice update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022 Apr;162(4):1334-42.[Abstract][Full Text]
94. Xie Y, Bowe B, Yan Y, et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ. 2019 May 29;365:l1580.[Abstract][Full Text]
95. Poly TN, Islam MM, Yang HC, et al. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int. 2019 Jan;30(1):103-14.[Abstract]
96. Chrysant SG. Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias. Expert Rev Cardiovasc Ther. 2019 May;17(5):345-51.[Abstract]
97. Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011 Apr;56(4):931-50.[Abstract]
98. Heidelbaugh JJ, Kim AH, Chang R, et al. Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol. 2012 Jul;5(4):219-32.[Abstract][Full Text]
99. Wilhelm SM, Rjater RG, Kale-Pradhan PB. Perils and pitfalls of long-term effects of proton pump inhibitors. Expert Rev Clin Pharmacol. 2013 Jul;6(4):443-51.[Abstract]
100. Wennogle L, Wysowskyj H, Steel DJ, et al. Regulation of central cholecystokinin recognition sites by guanyl nucleotides. J Neurochem. 1988 Mar;50(3):954-9.[Abstract]
101. Veettil SK, Sadoyu S, Bald EM, et al. Association of proton-pump inhibitor use with adverse health outcomes: a systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials. Br J Clin Pharmacol. 2022 Feb;88(4):1551-66.[Abstract][Full Text]
102. Yuan J, He Q, Nguyen LH, et al. Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies. Gut. 2021 Jun;70(6):1070-7.[Abstract]
103. Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology. 2019 Sep;157(3):682-691.e2.[Abstract][Full Text]
104. Hansen KE, Nieves JW, Nudurupati S, et al. Dexlansoprazole and esomeprazole do not affect bone homeostasis in healthy postmenopausal women. Gastroenterology. 2019 Mar;156(4):926-934.e6.[Abstract][Full Text]
105. Khan MA, Yuan Y, Iqbal U, et al. No association linking short-term proton pump inhibitor use to dementia: systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2020 May;115(5):671-8.[Abstract]
106. Ahn N, Nolde M, Krause E, et al. Do proton pump inhibitors increase the risk of dementia? A systematic review, meta-analysis and bias analysis. Br J Clin Pharmacol. 2023 Feb;89(2):602-16.[Abstract][Full Text]
107. Brown JP, Tazare JR, Williamson E, et al. Proton pump inhibitors and risk of all-cause and cause-specific mortality: a cohort study. Br J Clin Pharmacol. 2021 Aug;87(8):3150-61.[Abstract][Full Text]
108. Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016 May;65(5):740-8.[Abstract][Full Text]
109. Cappell MS, Friedel D. Initial management of acute upper gastrointestinal bleeding: from initial evaluation up to gastrointestinal endoscopy. Med Clin North Am. 2008 May;92(3):491-509, xi.[Abstract]
110. Al Dhahab H, McNabb-Baltar J, Al-Taweel T, et al. State-of-the-art management of acute bleeding peptic ulcer disease. Saudi J Gastroenterol. 2013 Sep-Oct;19(5):195-204.[Abstract][Full Text]
111. BioSpace. Edenbridge Pharmaceuticals announces U.S. FDA approval of Dartisla ODT (glycopyrrolate) orally disintegrating tablets. Dec 2021 [internet publication].[Full Text]
112. World Gastroenterology Organisation. World Gastroenterology Organisation global guidelines: Helicobacter pylori. May 2021 [internet publication].[Full Text]
113. World Society of Emergency Surgery. Perforated and bleeding peptic ulcer: WSES guidelines. 2020 [internet publication].[Full Text]
114. Jung HK, Kang SJ, Lee YC, et al. Evidence based guidelines for the treatment of Helicobacter pylori infection in Korea 2020. Korean J Intern Med. 2021 Jul;36(4):807-38.[Abstract][Full Text]
115. Joo MK, Park CH, Kim JS, et al. Clinical guidelines for drug-related peptic ulcer, 2020 revised edition. Gut Liver. 2020 Nov 15;14(6):707-26.[Abstract][Full Text]
116. Kato M, Ota H, Okuda M, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019 Aug;24(4):e12597.[Abstract][Full Text]
117. Boonpongmanee S, Fleischer DE, Pezzullo JC, et al. The frequency of peptic ulcer as a cause of upper-GI bleeding is exaggerated. Gastrointest Endosc. 2004 Jun;59(7):788-94.[Abstract]
